Today SomaLogic, Inc. announced an enhanced collaboration with NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, that builds on the companies’ ten-year partnership by bringing new clinical tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese population.
SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.
Sign up to receive our news releases
On May 12, 2020, Stephen Williams (SomaLogic), Claudia Langenberg (University of Cambridge), and Peter Ganz (UCSF) discussed key findings and motivations for the study “Plasma protein patterns as comprehensive indicators of health,” which was recently published in Nature Medicine. They also explored the implications of their findings for public health, particularly in the areas of diabetes and cardiovascular disease.
A recording of the webinar will be available soon.
More SomaLogic News
SomaScan proteomic technology is now broadly available to COVID-19 researchers and drug developers to expand and accelerate response to the pandemic
SomaLogic today launched a new initiative to deploy their proteomic technology against the coronavirus pandemic. The company is making its proprietary SomaScan® Assay available to biopharma companies, academic medical investigators, and government entities working on COVID-19/SARS-CoV-2 infection under simplified terms, with data from non-pharma studies to be shared rapidly and widely.
SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
Proteins in our blood could in future help provide a comprehensive way to assess our health status and predict the likelihood that we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at the University of California, San Francisco, Cambridge University in the UK and SomaLogic, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict a range of disease risks.
WEBINAR: The Liquid Liver Biopsy: Characterizing NASH and NAFLD with Serum Protein Biomarkers
On April 30, 2020, Dr. Steve Williams, Chief Medical Officer for SomaLogic, discussed how the SomaScan Assay can noninvasively and simultaneously predict all the key elements of the liver biopsy: liver fat, inflammation, hepatocyte ballooning and fibrosis based only on serum protein biomarkers.
WEBINAR: Proteomics the Missing Link between GWAS, EWAS and Disease Endpoints
On April 8, 2020, Karsten Suhre, Director of the Bioinformatics Core at Weill Cornell Medicine-Qatar, discussed how the SomaScan Assay can complement genome-wide association studies (GWAS) and epigenome-wide association studies (EWAS) to link genetic variants and DNA methylation patterns to disease endpoints.
WEBINAR: Aging and the Proteome, or How to Die Young at a Very Old Age
On March 4, 2020, Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine and Benoit Lehallier, Instructor in Neurology at Stanford University, discussed the findings of their Nature Medicine paper “Undulating changes in human plasma proteome profiles across the lifespan” and presented new data exploring how probing the proteome can help us to separate chronological age from biological age.
SomaLogic, a privately held precision health information company, announced today that it has appointed Anne Margulies, Harvard University Vice President and Chief Information Officer, Franck J. Moison, former Vice Chairman of Colgate-Palmolive, and private investor Richard “Rick” Post to its board of directors. All three bring distinct expertise and experience to help guide the next phase of SomaLogic’s growth.
SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.
SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
For older news and press releases, please visit our archive.